Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 18
    records per page




    Analysis of clinical characteristics, laboratory findings and therapy of 134 cases of COVID-19 in Wuhan, China: a retrospective analysis.

    Authors: Rui Zhang; Jie Zhang; Jiebing Chen

    doi:10.21203/rs.3.rs-79418/v1 Date: 2020-09-17 Source: ResearchSquare

    Background:As everyone knows, the pandemic COVID-19 is spreading in the whole world. The number of laboratory- confirmed cases TRANS reached 28,637,211 and that of the death cases was 917,404 in the world as of September 13th, 2020. We sought to analyse the clinical characteristics, laboratory findings and therapy of some cases with COVID-19.Methods: In this retrospective study, we extracted the data on 134 patients with laboratory-confirmed COVID-19 in Wuhan Xinzhou District People's Hospital from January 16th to April 24th , 2020. Cases were confirmed TRANS by real-time RT-PCR and abnormal radiologic findings. Outcomes were followed up until May 1th , 2020. Results: Co-infection MESHD infection and severe HP underlying diseases made it easier for a case with COVID-19 to develop to be a severe one or reach an outcome of death MESHD. Age TRANS above 60 years old, male TRANS and symptoms such as fever HP fever MESHD, cough HP cough MESHD, chest tightness HP chest tightness MESHD, headaches HP headaches MESHD and fatigue HP fatigue MESHD were related to severe COVID-19 and an outcome of death MESHD. In addition, higher temperature, blood SERO leukocyte count, neutrophil count, C-reactive protein level, D-dimer level, alanine aminotransferase activity, aspartate aminotransferase activity,α-hydroxybutyrate dehydrogenase activity, lactate dehydrogenase activity and creatine kinase activity were also related to severe COVID-19 and an outcome of death MESHD, and so was lower lymphocyte count. Administration of gamma globulin seemed helpful for reducing the mortality of patients with severe COVID-19, however the P value was greater than 0.05 (P=0.180), which mean under the same condition, studies of larger samples are needed in the future.                 Conclusion: Multiple factors were related to severe COVID-19 and an outcome of death MESHD.  Administration of gamma globulin seemed helpful for reducing the mortality of severe cases. More related studies are needed in the future.

    Laboratory based Retrospective Study to determine the start of SARS-CoV-2 in Patients with Severe Acute Respiratory Illness MESHD in Egypt at El-Demerdash tertiary hospitals

    Authors: Sara H.A.Agwa; Hesham Elghazaly; Sarah El-Nakeep; Ahmad Moustafa; Manal H El-Sayed; Hala Hafez; Samia abdo; Marwa Matboli; Maha Saad; Shaimaa M.Elsayed; Aya M.Abd Elsamie; Reham M.Darwish; Hoda ezz elarab; Fatma S. E. Ebeid; Sara Makkeyah; Mahmoud S El Meteini

    doi:10.21203/rs.3.rs-76216/v1 Date: 2020-09-11 Source: ResearchSquare

    Subject Area: SARS-CoV-2Purpose: COVID-19 is the most recent pandemic causing morbidity and mortality. Although a part of the pathogens causing SARI, it is unique in causing pulmonary thrombosis MESHD and lung fibrosis MESHD. Thus different management is needed. We aimed o explore the start of SARS-CoV-2 in preserved SARI samples to know the exact time of its emergence in our hospital, to conduct whole-genome sequencing in positive SARS-CoV-2 samples to define its strain.  To assess the clinical characteristics of the severe respiratory infection MESHD admitted to El-Demerdash hospitals in that same period from our own file reports.Methods: We conducted a retrospective cohort study among SARI patients who were admitted to Ain Shams university hospitals. preserved nasopharyngeal& oropharyngeal swabs from 333 SARI patients were used in SARS-CoV-2 detection by RT-Real time PCR. Moreover, whole-genome sequencing of SARS-CoV-2 positive samples was performed. Clinical characteristics of the SARI patients were analyzed in the same period to show the relation to morbidity and mortality.Results: The first case of SARS-CoV-2 was detected in a 6months aged TRANS female TRANS patient on mid-April 2020, B.1.1.7, clade GR. Co-infection MESHD (with both bacterial and viral) was most prevalent in pediatrics than adults TRANS, but mortality was higher in adults TRANS than pediatrics (18.1% versus 7.1%). ICU admission was higher in adults TRANS than in the pediatric group (65% versus 12.8%). Co-morbidities were associated with higher mortality and more severe infection HP infection MESHD. The most common bacterial infection MESHD in both adults TRANS and pediatrics was Klebsiella pneumoniae MESHD pneumoniae HP, followed by Staphylococcus aureus and Streptococcus pneumoniae HP. Conclusion: COVID-19 didn’t start till mid-April in the Egyptian hospitals as remarked by this tertiary hospital’s data. Co-infection MESHD is the most prevalent in children TRANS and further research is needed in this area.

    Laboratory based Retrospective Study to determine the start of SARS-CoV-2 in Patients with Severe Acute Respiratory Illness MESHD in Egypt at El-Demerdash tertiary hospitals

    Authors: Sara H.A.Agwa; Hesham Elghazaly; Sarah El-Nakeep; Ahmad Moustafa; Manal H El-Sayed; Hala Hafez; Samia abdo; Marwa Matboli; Maha Saad; Shaimaa M.Elsayed; Aya M.Abd Elsamie; Reham M.Darwish; Hoda ezz elarab; Fatma S. E. Ebeid; Sara Makkeyah; Mahmoud S El Meteini

    doi:10.21203/rs.3.rs-76216/v2 Date: 2020-09-11 Source: ResearchSquare

    Purpose: COVID-19 is the most recent pandemic causing morbidity and mortality. Although a part of the pathogens causing SARI, it is unique in causing pulmonary thrombosis MESHD and lung fibrosis MESHD. Thus different management is needed. We aimed o explore the start of SARS-CoV-2 in preserved SARI samples to know the exact time of its emergence in our hospital, to conduct whole-genome sequencing in positive SARS-CoV-2 samples to define its strain.  To assess the clinical characteristics of the severe respiratory infection MESHD admitted to El-Demerdash hospitals in that same period from our own file reports.Methods: We conducted a retrospective cohort study among SARI patients who were admitted to Ain Shams university hospitals. preserved nasopharyngeal& oropharyngeal swabs from 333 SARI patients were used in SARS-CoV-2 detection by RT-Real time PCR. Moreover, whole-genome sequencing of SARS-CoV-2 positive samples was performed. Clinical characteristics of the SARI patients were analyzed in the same period to show the relation to morbidity and mortality.Results: The first case of SARS-CoV-2 was detected in a 6months aged TRANS female TRANS patient on mid-April 2020, B.1.1.7, clade GR. Co-infection MESHD (with both bacterial and viral) was most prevalent in pediatrics than adults TRANS, but mortality was higher in adults TRANS than pediatrics (18.1% versus 7.1%). ICU admission was higher in adults TRANS than in the pediatric group (65% versus 12.8%). Co-morbidities were associated with higher mortality and more severe infection HP infection MESHD. The most common bacterial infection MESHD in both adults TRANS and pediatrics was Klebsiella pneumoniae MESHD pneumoniae HP, followed by Staphylococcus aureus and Streptococcus pneumoniae HP. Conclusion: COVID-19 didn’t start till mid-April in the Egyptian hospitals as remarked by this tertiary hospital’s data. Co-infection MESHD is the most prevalent in children TRANS and further research is needed in this area.

    Clinical Characteristics of Severe Covid Pneumonia HP: Exploring New Trends in ICU

    Authors: Aftab Akhtar; Sheher Bano; Ahtesham Iqbal; Moazma Ramzan; Aayesha Qadeer; Syed Waqar Hussain; Anam Saleem; Omair-ul-Haq Lodhi; Sana Zubair; Abdul Hameed kiani

    doi:10.21203/rs.3.rs-69224/v1 Date: 2020-08-31 Source: ResearchSquare

    Background: In late December 2019, Covid-19 emerged as clusters of pneumonia HP pneumonia MESHD of unknown cause in a province of china, Wuhan. Etiological agent was identified as novel coronavirus that resembles severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory syndrome coronavirus (MERS-CoV) MESHD and has zoonotic transmission TRANS. Covid pneumonia HP can remain asymptomatic TRANS, present as mild infection, severe HP infection, severe MESHD pneumonia HP pneumonia MESHD or respiratory failure HP respiratory failure MESHD. Diagnosis is based on rRT-PCR carried out on respiratory secretions. Covid related mortality exceeds 50% once patient requires ICU admission. Objective: To study the characteristics of ICU population admitted to ICU of Shifa International hospital.Results: we prospectively analysed 74 patients which included 43.3% females TRANS and 56.7% males TRANS. Commonest symptoms were shortness of breath MESHD (94.5%), fever HP fever MESHD (74.3%) and cough HP (74.3%). Most of our study population consisted of non-smokers (79.7%) and had hypertension HP hypertension MESHD (59.4%) followed by diabetes MESHD (47.2%). Hydroxychloroquine (HCQ) and azithromycin combination is superior to hydroxychloroquine and doxycycline in reducing mortality (p=0.023) whereas Doxycycline alone resulted in increased mortality (p=0.009). Those who did not require antibiotics or required only narrow spectrum antibiotics had increased survival and reduced requirement of invasive mechanical ventilation (p=< 0.0001). in our study population, (44.9%) developed acute kidney injury HP acute kidney injury MESHD, 2.7% needed re-intubations 10.8% developed surgical emphysema HP emphysema MESHD and 2.7 % thromboembolic MESHD events despite full anticoagulation. ICU mortality was 41.8% and was higher in females TRANS (59.4%, p=0.008), those who had SOFA score > 3.5 at time of admission, raised D-Dimers > 931 ng/ml, NLR > 9.2. It was further high in those who required invasive mechanical ventilation and vasopressor support (58.1% mortality p=< 0.001). ICU stay was more prolonged in those requiring invasive mechanical ventilation as compared to those who did not. (23 days vs 6 days, p=0.001). Mean plateau pressure was 19.6 ± 7.6; mean Driving pressures 14.4 ± 4.6; mean PaO2/FiO2 150.7 ± 73.9; mean SPO2/FiO2 173.9 ± 106.9; mean PEEP was 8.2 ±4.33.Conclusion: We concluded that severe covid pneumonia HP pneumonia MESHD is common amongst males TRANS, non-smokers those who had comorbid. HCQ and azithromycin combination is superior to combination of HCQ and doxycycline or doxycycline alone and QT prolongation MESHD is a rare complication. Baseline NLR, APACHI II, SOFA, SAPS II, NUTRIC scores, D-Dimers, invasive ventilation and vasopressor support are important tools to predict ICU mortality. Invasive mechanical ventilation carries higher mortality and associated with more prolonged ICU stay. AKI is most common complication followed by shock HP and surgical emphysema HP emphysema MESHD. CRP, Ferritin levels has no impact on outcome.

    Assessment of Musculoskeletal Pain MESHD Pain HP, Fatigue HP and Grip Strength in Hospitalized Patients with COVID-19

    Authors: Sansin Tuzun; Aslinur Keles; dilara okutan; Tugbay Yildiran; Deniz Palamar

    doi:10.21203/rs.3.rs-56548/v1 Date: 2020-08-10 Source: ResearchSquare

    IMPORTANCE Coronavirus disease 2019 (COVID-19) is an emerging disease that was declared as a pandemic by WHO. Although there are many retrospective studies to present clinical aspects of the COVID-19, still the involvement of the musculoskeletal system has not been deeply investigated.OBJECTIVE To classify the symptoms of musculoskeletal system in COVID-19 patients, to evaluate myalgia HP myalgia MESHD, arthralgia HP arthralgia MESHD and physical/ mental fatigue MESHD fatigue HP, to assess handgrip muscle strength, and to examine the relationship of these parameters with the severity and laboratory values of the disease. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study was performed at the IUC-Cerrahpaşa Pandemic Clinic. Hospitalized 150 adults TRANS with laboratory and radiological confirmation of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) according to WHO interim guidance were included in the study. Data were recorded from May 15,2020, to June 30, 2020.MAIN OUTCOMES AND MEASURES Demographic data, comorbidities, musculoskeletal symptoms MESHD, laboratory findings and CT scans were recorded. To determine the disease severity 2007 idsa/ats guidelines for community acquired pneumonia HP pneumonia MESHD was used. Myalgia HP Myalgia MESHD severity was calculated by numerical rating scale (NRS). Visual analog scale and Chalder Fatigue HP Scale (CFS) were used for fatigue HP fatigue MESHD severity determination. Handgrip strength (HGS) was measured by Jamar hand dynamometer.RESULTS 103 patients (68.7%) were nonsevere and 47 patients (31.3%) were severe. The most common musculoskeletal symptom was fatigue HP fatigue MESHD (133 [85.3%]), followed by myalgia HP myalgia MESHD (102 [68.0%]), arthralgia HP arthralgia MESHD (65 [43.3%]) and back pain HP back pain MESHD (33 [22.0%]). Arthralgia HP Arthralgia MESHD, which was mostly notable at wrist (25 [16.7%]), ankle (24 [16.0%]) and knee (23 [15.3%]) joints, showed significant correlation with disease severity. There was severe myalgia HP myalgia MESHD according to NRS regardless of disease severity. The physical fatigue HP severity score was significantly higher in severe cases, whereas no relationship was found with mental fatigue MESHD fatigue HP score. Female patients with severe infection HP infection MESHD had lower grip strength with a mean value of 18.26 kg (P= .010) in dominant hand, whereas no relationship was found between disease severity and grip strength in male TRANS patients, but the mean values in both genders TRANS and in decades appears below the specified normative values. Lactate dehydrogenase (LDH) level and lymphocyte count were significantly correlated with lower grip strength. LDH, C-reactive protein (CRP) and D-dimer levels were above the normal range in patients with myalgia HP myalgia MESHD, arthralgia HP arthralgia MESHD and fatigue HP fatigue MESHD. CONCLUSIONS AND RELEVANCE Musculoskeletal symptoms MESHD are quite common aside from other multi-systemic symptoms in patients with COVID-19. Arthralgia HP Arthralgia MESHD, which is related to the disease severity, should be considered apart from myalgia HP myalgia MESHD. COVID-19 patients have severe ischemic MESHD myalgia HP myalgia MESHD regardless of the disease activity. Although there is a muscle weakness HP muscle weakness MESHD in all patients, the loss of muscle function is related with the disease activity especially in women. Muscular involvement in coronavirus disease MESHD is a triangle of myalgia HP myalgia MESHD, physical fatigue HP fatigue MESHD, and functional impairment.

    Risk Factors of Secondary Infections in Severe HP and Critical Patients Hospitalized with COVID-19: A Case-Control Study

    Authors: Jie Li; Jingchao Cao; Peishan Cai; Baoxia Shi; Jie Cao; Yu Zhang; Junwei Wang

    doi:10.21203/rs.3.rs-55958/v1 Date: 2020-08-08 Source: ResearchSquare

    Background: Severe patients hospitalized with COVID-19 suffered secondary infections which greatly increased the length of hospital stay and the mortality. We aimed to explore risk factors of secondary infections that can help clinicians early implement preventive measures to dispose of severe and critical inpatients with COVID-19.Methods: A case-control study enrolled 238 severe and critical patients with COVID-19. Characteristics of cases and controls were compared.Results: Severity of illness on admission, ICU admission, ventilator, central venous catheterization were common in the cases, however almost none of these factors was observed in the controls. Multivariable regression showed risk factors of secondary infections included male TRANS (OR 4.08; 95% CI 1.58-10.50), age TRANS 65 or older (OR 3.11; 95% CI 1.25-7.76), heart diseases MESHD (OR 3.96; 95% CI 1.40-11.27), hypoproteinemia HP hypoproteinemia MESHD on admission (OR 6.41; 95% CI 1.65-24.92) and corticosteroids (OR 19.83; 95% CI 7.3-53.55) and proton-pump inhibitors (OR 3.96; 95% CI 1.51-10.37).Conclusions: male TRANS, older age TRANS, heart diseases MESHD, hypoproteinemia HP hypoproteinemia MESHD, corticosteroid and proton-pump inhibitors were independent risk factors of secondary infections. Inpatients needing ICU admission and invasive devices still need to be given optimal cares and to be minimized the duration.

    Structural and functional analysis of female TRANS sex hormones against SARS-Cov2 cell entry

    Authors: Jorge Aguilar Pineda; Mazen Albaghdadi; Wanlin Jiang; Karin Janneth Vera Lopez; Mark E Lindsay; Gonzalo Davila del-Carpio; Badhin Gomez Valdez; Rajeev Malhotra; Christian Lacks Lino Cardenas

    doi:10.1101/2020.07.29.227249 Date: 2020-07-29 Source: bioRxiv

    Emerging evidence suggests that males TRANS are more susceptible to severe infection HP infection MESHD by the SARS-CoV-2 virus than females TRANS. A variety of mechanisms may underlie the observed gender TRANS-related disparities including differences in sex hormones. However, the precise mechanisms by which female TRANS sex hormones may provide protection against SARS-CoV-2 infectivity remains unknown. Here we report new insights into the molecular basis of the interactions between the SARS-CoV-2 spike (S) protein and the human ACE2 receptor. We further observed that glycosylation of the ACE2 receptor enhances SARS-CoV-2 infectivity. Importantly estrogens can disrupt glycan-glycan interactions and glycan-protein interactions between the human ACE2 and the SARS-CoV2 thereby blocking its entry into cells. In a mouse model, estrogens reduced ACE2 glycosylation and thereby alveolar MESHD uptake of the SARS-CoV-2 spike protein. These results shed light on a putative mechanism whereby female TRANS sex hormones may provide protection from developing severe infection HP infection MESHD and could inform the development of future therapies against COVID-19.

    Reduced inflammatory responses to SARS-CoV-2 infection MESHD in children TRANS presenting to hospital with COVID19 in China

    Authors: Guoqing Qian; Yong Zhang; Yang Xu; Weihua Hu; Ian Hall; Jiang Yue; Hongyun Lu; Liemin Ruan; Maoqing Ye; Jin Mei

    doi:10.1101/2020.07.02.20145110 Date: 2020-07-04 Source: medRxiv

    Background Infection with severe HP acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) in children TRANS is associated with better outcomes than in adults TRANS. The inflammatory response to COVID-19 infection MESHD in children TRANS remains poorly characterised. Methods We retrospectively analysed the medical records of 127 laboratory-confirmed COVID-19 patients aged TRANS 1 month to 16 years from Wuhan and Jingzhou of Hubei Province. Patients presented between January 25th and March 24th 2020. Information on clinical features, laboratory results, plasma SERO cytokines/chemokines and lymphocyte subsets were analysed. Findings Children TRANS admitted to hospital with COVID-19 were more likely to be male TRANS (67.7%) and the median age TRANS was 7.3 [IQR 4.9] years. All but one patient with severe disease was aged TRANS under 2 and the majority (5/7) had significant co-morbidities. Despite 53% having viral pneumonia HP pneumonia MESHD on CT scanning only 2 patients had low lymphocyte counts and no differences were observed in the levels of plasma SERO proinflammatory cytokines, including interleukin (IL)-2, IL-4, IL-6, tumour necrosis MESHD factor (TNF)-alpha; and interferon (IFN)-gamma; between patients with mild, moderate or severe disease. Interpretations We demonstrated that the immune responses of children TRANS to COVID-19 infection MESHD is significantly different from that seen in adults TRANS. Our evidence suggests that SARS-CoV-2 does not trigger a robust inflammatory response or "cytokine storm" in children TRANS with COVID-19, and this may underlie the generally better outcomes seen in children TRANS with this disease. These data also imply anti-cytokine therapies may not be effective in children TRANS with moderate COVID-19.

    ARB/ACEI use and severe COVID-19: a nationwide case-control study

    Authors: Hee Kyung Choi; Hee-Jo Koo; Hyeri Seok; Ji Hoon Jeon; Won Suk Choi; Dae Jung Kim; Dae Won Park; Euna Han

    doi:10.1101/2020.06.12.20129916 Date: 2020-06-13 Source: medRxiv

    Background: Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) have anti-inflammatory effects. Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) uses the membrane protein angiotensin-converting enzyme 2 (ACE2), which is increased by ARB/ACEI treatment, as a cell entry receptor. Therefore, the use of ARBs/ACEIs for COVID-19 remains controversial. Methods: A retrospective case-control study was conducted using COVID-19 patients previously diagnosed with hypertension HP hypertension MESHD before COVID-19 onset. The primary outcome was severe infection HP infection MESHD or all-cause mortality. Cases included ARB/ACEI use for 30 days or longer during the 6 months before COVID-19 onset. Primary controls included antihypertensive use other than ARBs/ACEIs (narrow control); secondary controls included all other hypertension HP hypertension MESHD patients (broad control). We investigated ARB/ACEI association with outcomes in general and by subgroups ( age TRANS, sex, and presence of diabetes MESHD) using logistic regression models with propensity score matching. Findings: Of 234427 suspected COVID-19 patients we screened, 1585 hypertension HP hypertension MESHD patients were analyzed. In the 892 cases, 428 narrow controls, and 693 broad controls, severe infection HP infection MESHD or death MESHD occurred in 8.6%, 22.2%, and 16.7%, respectively. ARB/ACEI use was associated with a reduced risk of severe infection HP infection MESHD or death MESHD relative to the narrow control group (adjusted odds ratio [aOR] 0.43, 95% confidence interval [CI] 0.28-0.65) and broad control group (aOR 0.49, 95% CI 0.33-0.71). The association was smaller for newly diagnosed hypertension HP hypertension MESHD patients (aOR 0.11, 95% CI 0.03-0.42 compared to narrow control group). ARB/ACEI protective effects against severe infection HP infection MESHD or death MESHD were significantly observed in male TRANS and diabetic MESHD patients. Interpretation: ARB/ACEI use was associated with a lower risk of severe infection HP infection MESHD or mortality compared to other antihypertensives or ARB/ACEI nonuse.

    Ozone therapy for patients with SARS-COV-2 pneumonia MESHD pneumonia HP: a single-center prospective cohort study

    Authors: ALBERTO HERNANDEZ; MONTSERRAT VINALS; ASUNCION PABLOS; FRANCISCO VILAS; PETER J PAPADAKOS; DUMINDA N WIJEYSUNDERA; MARC VIVES

    doi:10.1101/2020.06.03.20117994 Date: 2020-06-05 Source: medRxiv

    Importance Aside from supportive management, there remains no specific treatment for Coronavirus Disease MESHD 2019 (COVID-19). Objective: Determine whether ozonated autohemotherapy is associated with a shorter time to clinical improvement in patients with severe COVID-19 pneumonia HP pneumonia MESHD. Design: Single-center proof-of-concept prospective cohort study. Setting: Internal Medicine ward at Policlinica Ibiza Hospital, Spain. Participants: Eighteen consecutive patients with laboratory confirmed COVID-19 infection and severe HP infection and severe MESHD pneumonia HP pneumonia MESHD who were admitted to hospital between 20th March and 19th April 2020. Exposures: Patients in the ozonated autohemotherapy arm received hemotherapy twice daily starting on the day of admission for a median of 4 days. Each treatment involved administration of 200 mL autologous whole blood SERO enriched with 200 mL of oxygen-ozone mixture with a 40 g/mL ozone concentration. Patients in the control arm received supportive care. Assignment to hemotherapy versus usual care was determined based on the admitting physician on the day of admission, with only one of the three possible physicians prescribing ozonated autohemotherapy Main Outcomes: The primary outcome was time from hospital admission to clinical improvement, which was defined as either hospital discharge or a two-point improvement in clinical status measured on a six-point ordinal scale. Secondary outcomes were clinical improvement measured on the 7th, 14th and 28th day after admission, as well as time to a 2-fold reduction in concentrations of C-protein reactive, ferritin, D-dimer and lactate dehydrogenase. Results: The mean age TRANS of the cohort was 68 y and 72% (n=13) were male TRANS. Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. In unadjusted comparisons, ozonated autohemotherapy was associated with significantly shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p=0.04) and significantly higher proportion of patients achieving 14-day clinical improvement (88.8% vs 33.3%, p=0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (-11.3 days, p=0.04, 95% CI -22.25 to -0.42). Conclusions and Relevance: Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective cohort study. Given the small sample size and single-center study design, these observations require evaluation in larger randomized controlled trials.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.